CTLA4 and neoplasm: Checkpoint inhibitors increase endogenous anti-tumor activity by blocking components of the immune system, including cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein-1 (PD-1), or ligand 1 (PD-L1).